Company Profile
Svelte Medical Systems, Inc. is a US-based manufacturer of drug-eluting coronary stent systems, headquartered in New Providence, New Jersey. Founded in 2007 by the Fischell family (Robert, David, and Tim Fischell), the privately held company developed next-generation balloon-expandable stents designed for direct stenting and transradial intervention. In October 2024, all assets of Svelte Medical Systems were acquired by Advanced Bifurcation Systems, Inc., adding Svelte's FDA-approved drug-eluting stent portfolio to ABS's bifurcation-focused platform.
Core Products ＆ Technologies
Drug-Eluting Coronary Stent Platforms
• SLENDER IDS® (Integrated Delivery System): Fixed-wire, all-in-one coronary stent delivery system achieving ultra-low crossing profiles as low as 0.029"; eliminates need for conventional guidewires and predilatation balloons in suitable lesions; facilitates transradial intervention and direct stenting
• DIRECT RX® (Rapid Exchange System): Rapid-exchange drug-eluting stent platform providing conventional over-the-wire compatibility with Svelte's low-profile stent technology
• Bioresorbable Amino-Acid Polymer Coating: Proprietary drug carrier composed of naturally occurring amino acids (PEA) eluting sirolimus; resorbed via enzymolysis over approximately 9–12 months, avoiding bulk degradation and pH change associated with traditional PLGA polymers
• Balloon Control Bands (BCBs): Proprietary elastic bands enveloping low-compliant balloon shoulders to control expansion, limit dog-boning, and enable safe high-pressure post-dilatation
Clinical ＆ Regulatory Validation
• OPTIMIZE Randomized Controlled Trial: Prospective, single-blind, randomized, active-control, multicenter study (NCT03190473) enrolling 1,630 subjects; demonstrated non-inferiority to Xience / Promus everolimus-eluting stents for target lesion failure at 12 months; results published in Circulation: Cardiovascular Interventions (2021)
• DIRECT II Study: European multicenter randomized trial demonstrating non-inferiority of Svelte IDS to Resolute Integrity zotarolimus-eluting stent for in-stent late lumen loss at 6 months; 0% clinically driven MACE reported through 2 years in DIRECT I first-in-human study
Market Position ＆ Certifications
Svelte Medical Systems held a specialized position in the highly deliverable coronary stent market, competing with Abbott (Xience), Boston Scientific (Synergy), Medtronic (Resolute), and Biotronik. Key strengths include:
• 17+ years of coronary stent innovation heritage
• First-in-class delivery: First significant advance in coronary stent delivery since rapid-exchange systems, integrating guidewire and stent delivery for ultra-low profiles
• Regulatory compliance: US FDA Premarket Approval (PMA) received December 2021; CE Mark certified in Europe; PMDA approved in Japan
• Clinical evidence: Published randomized trial data demonstrating non-inferior safety and efficacy against market-leading DES platforms
• Strategic acquisition value: FDA-approved DES portfolio and global regulatory filings acquired by Advanced Bifurcation Systems to accelerate commercial presence in interventional cardiology
Corporate Timeline
2007 — Founded in New Providence, New Jersey by the Fischell family
2009 — Closed Series A financing totaling USD 20 million
2014 — Completed later-stage venture financing; advanced SLENDER IDS platform through clinical development
2017 — DIRECT II European study completed 6-month follow-up demonstrating non-inferiority
2021 — Received FDA Premarket Approval (PMA) for drug-eluting coronary stent systems; OPTIMIZE trial results published in peer-reviewed journal
2024 — All assets acquired by Advanced Bifurcation Systems, Inc. (October)
2026 — Acquisition integration completed and announced by ABS (April 27), positioning combined entity among select global companies with FDA-approved drug-eluting coronary stent
Target Markets ＆ Applications
• Coronary Artery Disease: Percutaneous coronary intervention for de novo and restenotic lesions in native coronary arteries
• Transradial Intervention (TRI): Ultra-low-profile systems enabling radial artery access with downsized catheters, reducing bleeding complications and improving patient comfort
• Direct Stenting: Lesions amenable to direct stenting without predilatation, streamlining procedure steps and reducing contrast use, radiation exposure, and procedural time
• Small Vessel ＆ Complex Anatomy: Low-profile delivery suitable for tortuous vessels and slender intervention approaches
• Global Interventional Cardiology: Regulatory-approved platforms for the US, European, and Japanese markets via ABS commercial infrastructure
Contact Information
Global Headquarters
Address: 675 Central Avenue, Suite 2, New Providence, New Jersey 07974, USA
Phone: +1 908 264 2195
Email: info@advancedbifurcation.com
Website: www.advancedbifurcation.com
